Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study

Recent treatment advances in HER2-positive metastatic breast cancer: a clinical approach

Verma, Sunil
Landaverde Recinos, Denis

May 2012

The use of targeted therapy directed against HER2 is currently the standard of care in patients with...

Efficacy of Trastuzumab Emtansine Therapy in Sequantial Treatment in Patients with HER2-Positive Metastatic Breast Cancer

Serdar ATA
Burcu ARSLAN BENLİ
Oğuzhan KESEN
Ahmet Ziya BAYHAN
Hakan DEMİR
Ömer DEMİROĞLU
Ali Alper SOLMAZ
Timuçin ÇİL
Berna BOZKURT DUMAN

April 2023

Aim: The aim of this study was to evaluate the efficacy of Lapatinib, trastuzumab emtansine (T-DM1) ...

Targeting HER2 as a therapeutic strategy for breast cancer: A paradigmatic shift of drug development in oncology

De Laurentiis M.
Cancello G.
Zinno L.
Montagna E.
Malorni L.
Esposito A.
Pennacchio R.
Silvestro L.
Giuliano M.
Giordano A.
Caputo F.
Accurso A.
De Placido S.

January 2005

Targeted therapies are causing a dramatic change in cancer drug development. Trastuzumab, a humanise...

Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study

Carabante-Ocón, F
Saez-Lara, E
Burgos-Garcia, L
Villar-Chamorro, E
Casaus-Hazañas, A
Luna, S
Martínez, C

June 2007

Objective: To study the benefit of trastuzumab in monotherapy or combined with different chemotherap...

Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis

Han Y
Wang J
Liu W
Yuan P
Li Q
Zhang P
Ma F
Luo Y
Fan Y
Chen S
Cai R
Li Q
Xu B

May 2019

Yiqun Han,1 Jiayu Wang,1 Weiming Liu,2 Peng Yuan,1 Qing Li,1 Pin Zhang,1 Fei Ma,1 Yang Luo,1 Ying Fa...

Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies

Fabi A.
Metro G.
Ferretti G.
Giannarelli D.
Di Cosimo S.
Papaldo P.
Mottolese Marcella
Carlini P.
Felici A.
Russillo M.
Cognetti F.

January 2008

Though preclinical evidence supports the protracted use of trastuzumab to reach sustained anti-tumor...

First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study

Aitelhaj, Meryem
Lkhoyaali, Siham
Rais, Ghizlane
Boutayeb, Saber
Errihani, Hassan

October 2016

Breast cancer is the most common malignant disease and among the most frequent causes of cancer mort...

Study of the combination gemcitabine and trastuzumab in the treatment of HER2+ metastatic breast cancer

Menjón-Beltrán, S
Olivencia-Dueso, R
González-Jiménez, E
Titos, MJ

June 2007

Poster Presentation. This article is part of the supplement: VII Madrid Breast Cancer Conference: Ch...

Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study.

Campiglio M.
Bufalino R.
Sandri M.
Ferri E.
Aiello RA.
De Matteis A.
Mottolese M.
De Placido S.
Querzoli P.
Jirillo A.
Bottini A.
Fantini M.
Bonetti A.
Pedani F.
Mauri M.
Molino A.
Ferro A.
Pupa SM.
Sasso M.
M\ue9nard S.
Balsari A.
Tagliabue E.
Mustacchi G.
Zanconati F.
Demetra group.

January 2011

Recent studies have reported the potential clinical utility for metastatic breast cancer (MBC) patie...

Trastuzumab beyond progression in HER2-positive metastatic breast cancer

Manwar Alnaqqash

January 2021

The data about continuing trastuzumab treatment beyond progression in HER2-positive breast cancer ar...

Use of trastuzumab in HER2-positive metastatic breast cancer beyond disease progression: a systematic review of published studies

Mannocci, Alice
De Feo, Emma
De Waure, Chiara (ORCID:0000-0002-4346-1494)
Specchia, Maria Lucia (ORCID:0000-0002-3859-4591)
Gualano, Maria Rosaria
Barone, Carlo Antonio
Ricciardi, Gualtiero (ORCID:0000-0002-5655-688X)
La Torre, Giuseppe

January 2010

Aims and background. Trastuzumab, a humanized monoclonal antibody directed against the extracellula...

Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

Bighin, C
Pronzato, P
Del Mastro, L

January 2013

Hurvitz SA, Dirix L, Kocsis J et al. Phase II randomised study of trastuzumab emtansine versus trast...

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Piccart-Gebhart, Martine
Procter, Marion
Leyland-Jones, Brian
Goldhirsch, Aron
Untch, M.
Smith, Ian
Gianni, L.
Baselga, J
Bell, Richard H
Jackisch, C.
Cameron, David A
Dowsett, Mitch
Barrios, CH
Steger, G.
Huang, C.-S.
Andersson, M
Inbar, M.
Lichinitser, Michail
Lang, Istvan
Nitz, U.
Iwata, Hiroji
Thomssen, C.
Lohrisch, C
Suter, T.
Rüschoff, Josef
Sütö, T.
Greatorex, V.
Ward, David
Straehle, Carolyn
McFadden, E.
Dolci, Stella
Gelber, R D
HERA study team

October 2005

BACKGROUND: Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in ad...

Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology.

DE LAURENTIIS, MICHELINO
CANCELLO G
ZINNO L
MONTAGNA E
MALORNI L
ESPOSITO A
PENNACCHIO R
SILVESTRO L
GIULIANO, MARIO
GIORDANO A
CAPUTO F
ACCURSO A
DE PLACIDO, SABINO

January 2005

Targeted therapies are causing a dramatic change in cancer drug development. Trastuzumab, a humanize...

Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research

Goel, Shom
Chirgwin, Jacquie
Francis, Prudence
Stuart-Harris, Robin
Dewar, Joanna
Mileshkin, Linda
Snyder, Raymond
Michael, Michael
Koczwara, Bogda

February 2016

The management of HER2-positive metastatic breast cancer, a disease renowned for its aggressive natu...

Recent treatment advances in HER2-positive metastatic breast cancer: a clinical approach

Verma, Sunil
Landaverde Recinos, Denis

May 2012

The use of targeted therapy directed against HER2 is currently the standard of care in patients with...

Efficacy of Trastuzumab Emtansine Therapy in Sequantial Treatment in Patients with HER2-Positive Metastatic Breast Cancer

Serdar ATA
Burcu ARSLAN BENLİ
Oğuzhan KESEN
Ahmet Ziya BAYHAN
Hakan DEMİR
Ömer DEMİROĞLU
Ali Alper SOLMAZ
Timuçin ÇİL
Berna BOZKURT DUMAN

April 2023

Aim: The aim of this study was to evaluate the efficacy of Lapatinib, trastuzumab emtansine (T-DM1) ...

Targeting HER2 as a therapeutic strategy for breast cancer: A paradigmatic shift of drug development in oncology

De Laurentiis M.
Cancello G.
Zinno L.
Montagna E.
Malorni L.
Esposito A.
Pennacchio R.
Silvestro L.
Giuliano M.
Giordano A.
Caputo F.
Accurso A.
De Placido S.

January 2005

Targeted therapies are causing a dramatic change in cancer drug development. Trastuzumab, a humanise...

Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study

Carabante-Ocón, F
Saez-Lara, E
Burgos-Garcia, L
Villar-Chamorro, E
Casaus-Hazañas, A
Luna, S
Martínez, C

June 2007

Objective: To study the benefit of trastuzumab in monotherapy or combined with different chemotherap...

Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis

Han Y
Wang J
Liu W
Yuan P
Li Q
Zhang P
Ma F
Luo Y
Fan Y
Chen S
Cai R
Li Q
Xu B

May 2019

Yiqun Han,1 Jiayu Wang,1 Weiming Liu,2 Peng Yuan,1 Qing Li,1 Pin Zhang,1 Fei Ma,1 Yang Luo,1 Ying Fa...

Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies

Fabi A.
Metro G.
Ferretti G.
Giannarelli D.
Di Cosimo S.
Papaldo P.
Mottolese Marcella
Carlini P.
Felici A.
Russillo M.
Cognetti F.

January 2008

Though preclinical evidence supports the protracted use of trastuzumab to reach sustained anti-tumor...

First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study

Aitelhaj, Meryem
Lkhoyaali, Siham
Rais, Ghizlane
Boutayeb, Saber
Errihani, Hassan

October 2016

Breast cancer is the most common malignant disease and among the most frequent causes of cancer mort...

Study of the combination gemcitabine and trastuzumab in the treatment of HER2+ metastatic breast cancer

Menjón-Beltrán, S
Olivencia-Dueso, R
González-Jiménez, E
Titos, MJ

June 2007

Poster Presentation. This article is part of the supplement: VII Madrid Breast Cancer Conference: Ch...

Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study.

Campiglio M.
Bufalino R.
Sandri M.
Ferri E.
Aiello RA.
De Matteis A.
Mottolese M.
De Placido S.
Querzoli P.
Jirillo A.
Bottini A.
Fantini M.
Bonetti A.
Pedani F.
Mauri M.
Molino A.
Ferro A.
Pupa SM.
Sasso M.
M\ue9nard S.
Balsari A.
Tagliabue E.
Mustacchi G.
Zanconati F.
Demetra group.

January 2011

Recent studies have reported the potential clinical utility for metastatic breast cancer (MBC) patie...

Trastuzumab beyond progression in HER2-positive metastatic breast cancer

Manwar Alnaqqash

January 2021

The data about continuing trastuzumab treatment beyond progression in HER2-positive breast cancer ar...

Use of trastuzumab in HER2-positive metastatic breast cancer beyond disease progression: a systematic review of published studies

Mannocci, Alice
De Feo, Emma
De Waure, Chiara (ORCID:0000-0002-4346-1494)
Specchia, Maria Lucia (ORCID:0000-0002-3859-4591)
Gualano, Maria Rosaria
Barone, Carlo Antonio
Ricciardi, Gualtiero (ORCID:0000-0002-5655-688X)
La Torre, Giuseppe

January 2010

Aims and background. Trastuzumab, a humanized monoclonal antibody directed against the extracellula...

Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

Bighin, C
Pronzato, P
Del Mastro, L

January 2013

Hurvitz SA, Dirix L, Kocsis J et al. Phase II randomised study of trastuzumab emtansine versus trast...

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Piccart-Gebhart, Martine
Procter, Marion
Leyland-Jones, Brian
Goldhirsch, Aron
Untch, M.
Smith, Ian
Gianni, L.
Baselga, J
Bell, Richard H
Jackisch, C.
Cameron, David A
Dowsett, Mitch
Barrios, CH
Steger, G.
Huang, C.-S.
Andersson, M
Inbar, M.
Lichinitser, Michail
Lang, Istvan
Nitz, U.
Iwata, Hiroji
Thomssen, C.
Lohrisch, C
Suter, T.
Rüschoff, Josef
Sütö, T.
Greatorex, V.
Ward, David
Straehle, Carolyn
McFadden, E.
Dolci, Stella
Gelber, R D
HERA study team

October 2005

BACKGROUND: Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in ad...

Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology.

DE LAURENTIIS, MICHELINO
CANCELLO G
ZINNO L
MONTAGNA E
MALORNI L
ESPOSITO A
PENNACCHIO R
SILVESTRO L
GIULIANO, MARIO
GIORDANO A
CAPUTO F
ACCURSO A
DE PLACIDO, SABINO

January 2005

Targeted therapies are causing a dramatic change in cancer drug development. Trastuzumab, a humanize...

Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research

Goel, Shom
Chirgwin, Jacquie
Francis, Prudence
Stuart-Harris, Robin
Dewar, Joanna
Mileshkin, Linda
Snyder, Raymond
Michael, Michael
Koczwara, Bogda

February 2016

The management of HER2-positive metastatic breast cancer, a disease renowned for its aggressive natu...

Recent treatment advances in HER2-positive metastatic breast cancer: a clinical approach

Verma, Sunil
Landaverde Recinos, Denis

May 2012

The use of targeted therapy directed against HER2 is currently the standard of care in patients with...

Efficacy of Trastuzumab Emtansine Therapy in Sequantial Treatment in Patients with HER2-Positive Metastatic Breast Cancer

Serdar ATA
Burcu ARSLAN BENLİ
Oğuzhan KESEN
Ahmet Ziya BAYHAN
Hakan DEMİR
Ömer DEMİROĞLU
Ali Alper SOLMAZ
Timuçin ÇİL
Berna BOZKURT DUMAN

April 2023

Aim: The aim of this study was to evaluate the efficacy of Lapatinib, trastuzumab emtansine (T-DM1) ...

Targeting HER2 as a therapeutic strategy for breast cancer: A paradigmatic shift of drug development in oncology

De Laurentiis M.
Cancello G.
Zinno L.
Montagna E.
Malorni L.
Esposito A.
Pennacchio R.
Silvestro L.
Giuliano M.
Giordano A.
Caputo F.
Accurso A.
De Placido S.

January 2005

Targeted therapies are causing a dramatic change in cancer drug development. Trastuzumab, a humanise...

Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study

Abstract

Extracted data

Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study

Abstract

Extracted data

Topics

Related items

Topics

Related items